BioWorld. Link to homepage.
BioWorld
BioWorld MedTech
BioWorld Asia
BioWorld Science
Data Snapshots
BioWorld
BioWorld MedTech
Infographics: Dynamic digital data analysis
Special reports
Infographics: Dynamic digital data analysis
Women's health
China's GLP-1 landscape
PFA re-energizes afib market
China CAR T
Alzheimer's disease
Israel
Rise of obesity
Radiopharmaceuticals
Biosimilars
Aging
IVDs on the rise
Coronavirus
Artificial intelligence
Premium reports
BioWorld Financings Reports
Disease Incidence & Prevalence Summaries
BioWorld. Link to homepage.
sign in
Sign Out
My Account
Subscribe
BioWorld - Sunday, December 1, 2024
See today's BioWorld Asia
Home
» Riboquark enrolling pivotal study of siRNA ocular neuroprotectant in China
X
Upgrade your daily dose of biopharma and medtech news
Subscribe to BioWorld™ news services
See subscription options
To read the full story,
subscribe
or
sign in
.
Riboquark enrolling pivotal study of siRNA ocular neuroprotectant in China
Nov. 22, 2017
By
David Ho
No Comments
HONG KONG – Kunshan Riboquark Pharmaceutical Technology Co. Ltd. enrolled the first patient in China for its global pivotal phase II/III study of ocular neuroprotectant candidate QPI-1007.
BioWorld Asia
